Search

Your search keyword '"Connolly, Anne M."' showing total 282 results

Search Constraints

Start Over You searched for: Author "Connolly, Anne M." Remove constraint Author: "Connolly, Anne M." Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
282 results on '"Connolly, Anne M."'

Search Results

1. Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophy.

2. Continued safety and long-term effectiveness of onasemnogene abeparvovec in Ohio

3. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.

4. Access to novel therapies for Duchenne muscular dystrophy—Insights from expert treating physicians

5. Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy

6. Findings from the Longitudinal CINRG Becker Natural History Study

7. Moving Beyond the 2018 Minimum International Care Considerations for Osteoporosis Management in Duchenne Muscular Dystrophy (DMD): Meeting Report from the 3rd International Muscle-Bone Interactions Meeting 7th and 14th November 2022

8. Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients With Duchenne Muscular Dystrophy

9. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis

12. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

13. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

14. SNUPN deficiency causes a recessive muscular dystrophy due to RNA mis-splicing and ECM dysregulation.

16. Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

17. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study

20. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)

23. Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy

26. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy

28. Contributors

29. Natural history of infantile‐onset spinal muscular atrophy

30. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

34. Mutations in sphingosine-1-phosphate lyase cause nephrosis with ichthyosis and adrenal insufficiency

37. Rasch Analysis of the Pediatric Quality of Life Inventory 4.0 Generic Core Scales Administered to Patients With Duchenne Muscular Dystrophy

39. Validity and Reliability of the Neuromuscular Gross Motor Outcome

40. Clinical and Molecular Spectrum Associated with COL6A3 c.7447A>G p.(Lys2483Glu) Variant: Elucidating its Role in Collagen VI-related Myopathies

41. Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

42. Findings from the Longitudinal CINRG Becker Natural History Study

43. Moving Beyond the 2018 Minimum International Care Considerations for Osteoporosis Management in Duchenne Muscular Dystrophy (DMD): Meeting Report from the 3rd International Muscle-Bone Interactions Meeting 7th and 14th November 2022

47. OUTCOME RELIABILITY IN NON-AMBULATORY BOYS/MEN WITH DUCHENNE MUSCULAR DYSTROPHY

48. Treatment for Spinal Muscular Atrophy Using Onasemnogene Abeparvovec.

50. Ataluren treatment of patients with nonsense mutation dystrophinopathy

Catalog

Books, media, physical & digital resources